NYSE$BHC

Bausch Health Companies Inc · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

Bausch Health's third-quarter performance reflected resilience with revenue of $2.046 billion, a decrease of 3% but an organic increase of 2%, driven by growth in key segments and strategic debt reduction.

Bausch Health reported a revenue of $2.046 billion for Q3 2022, a 3% decrease compared to Q3 2021, but showed a 2% increase on an organic basis. The company highlighted top-line improvements in several segments and a successful debt exchange offer that reduced debt by $2.5 billion. They have updated full year guidance.

  • Revenues of $2.046 billion, down 3% reported, up 2% organic basis
  • Third quarter sales improved sequentially, notably Salix, International, and Solta
  • Successful debt exchange offer reduces debt by $2.5 billion
  • Company updates full year guidance

Headline financials

Total Revenue

$2.05B

Previous: $2.11B-3.1%
EPS (adj)

$0.76

Previous: $1.15-33.9%
Adjusted EBITDA

$766M

Previous: $885M-13.4%
Cash from Operations

-$1.26B

No prior period
Capital Expenditures

-$152M

Previous: -$191M+20.4%
Free Cash Flow

$247M

Previous: -$3M+8333.3%
Net Income

$399M

Previous: $188M+112.2%
Operating Income

$244M

Previous: $574M-57.5%
Gross Profit

$1.46B

Previous: $1.53B-4.4%
Cash & Equivalents

$486M

Previous: $690M-29.6%
Total Assets

$26.3B

Previous: $29.3B-10.1%
Stock-Based Comp

$33M

Previous: $33M+0.0%

Revenue & EPS history

Bausch Health · Revenue · Quarterly

$2.05B

Q3 2022-3.1%vs Q3 2021
Beat estimate in 12 of 15 quarters(80%)
ActualEstimate

Revenue by segment

Bausch Health · $1.72B total across 3 segments · Q3 2022

  • Bausch + Lomb/International
    $942M-0.7%
  • Salix
    $544M+3.2%
  • Diversified Products
    $238M+6.3%

Forward guidance

Bausch Health updated its consolidated guidance for the full year 2022 as follows: •Full year revenue range of $8.0 - $8.17 billion compared with prior guidance of $8.05 - $8.22 billion •Full year revenues flat to up 2% on an organic basis (unchanged) •Full year Adjusted EBITDA (non-GAAP)1 range of $2.99 - $3.09 billion compared with prior guidance of $3.02 - $3.12 billion

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

+0.2%

Avg return

Earnings day

-0.6%

Avg return

5 days after

-1.9%

Avg return

30 days after

51%

35 / 68 earnings

Positive

+30.6%

Q1 2017

Best reaction

-21.5%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+10.9%+0.9%-4.1%
Q4 2025-4.5%-2.7%-19.1%
Q3 2025+12.4%+14.2%+7.6%
Q1 2025+0.0%-10.6%-14.5%
Q4 2024+10.3%+15.8%+10.0%
Q3 2024+12.7%+13.5%+2.6%
Q2 2024-6.6%-10.6%-1.7%
Q1 2024-10.6%-15.3%-25.0%
Q4 2023+5.9%+5.9%+10.3%
Q3 2023+6.9%+2.4%+4.0%
Q2 2023-2.9%-4.6%-9.3%
Q1 2023-21.2%-20.8%+11.2%
Q4 2022+10.8%+7.8%-16.3%
Q3 2022+7.5%+8.4%+21.4%
Q2 2022-3.3%+2.9%+14.7%
Q1 2022-21.5%-16.0%-35.0%
Q4 2021-1.9%+1.9%-3.3%
Q3 2021-4.5%-1.9%-17.8%
Q2 2021-15.5%-10.1%-0.7%
Q1 2021-10.8%-10.6%+0.9%
Q4 2020-0.9%+0.6%-1.8%
Q3 2020-3.1%-4.0%+11.0%
Q2 2020-7.2%-9.2%-16.3%
Q1 2020-1.8%+0.2%+12.4%
Q4 2019-5.8%-7.3%-51.3%
Q3 2019+0.8%+1.1%+10.6%
Q2 2019-4.0%-3.0%-6.9%
Q1 2019+8.7%+8.0%-9.0%
Q4 2018-6.7%-7.3%-2.0%
Q3 2018+6.1%+6.4%-5.2%
Q2 2018+5.4%-2.9%-7.3%
Q1 2018+11.5%+14.8%+37.4%
Q4 2017-17.5%-16.8%-13.9%
Q3 2017+23.6%+27.7%+46.4%
Q2 2017-8.5%-9.6%-12.9%
Q1 2017+30.6%+40.0%+36.6%
Q4 2016-18.7%-21.8%-33.7%
Q3 2016-15.9%-5.9%-19.3%
Q2 2016+21.7%+11.0%+33.5%
Q1 2016-17.1%-16.3%-18.6%
Q4 2015-7.4%
Q3 2015-17.4%
Q2 2015+5.4%
Q1 2015+5.6%
Q4 2014+14.7%
Q3 2014+8.5%
Q2 2014-6.1%
Q1 2014-1.6%
Q4 2013-1.0%
Q3 2013+2.0%
Q2 2013+6.2%
Q1 2013+1.8%
Q4 2012+1.3%
Q3 2012-2.6%
Q2 2012+2.2%
Q1 2012+2.1%
Q4 2008+6.3%
Q4 2010+6.3%
Q4 2011+6.3%
Q3 2011-2.9%
Q2 2011+3.9%
Q1 2010+0.0%
Q1 2011+6.3%
Q3 2010-5.4%
Q3 2009-5.4%
Q2 2009+2.0%
Q2 2010+2.0%
Q4 2009+2.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro